For other clinical features including sex, BMI/obesity, baseline kidney disease, duration of diabetes, baseline HbA1c, background glucose lowering medications, and prior history of microvascular disease, the overall body of evidence from meta-analyses does not provide robust evidence to support differential effects of GLP1-RA on CVD outcomes (Table 1). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.